700 breast cancer patients join study to track how CDK4/6 drugs work in real life
NCT ID NCT04526587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 700 adults with advanced or metastatic breast cancer who are taking CDK4/6 inhibitors (ciclib drugs). Researchers collect blood, tissue, and fluid samples to understand how the cancer responds, why resistance develops, and how well patients do over time. The goal is to learn more about the disease and improve future treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a drug that blocks HER proteins re-sensitize resistant breast cancer to hormone therapy?
- Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer
- Could a gentler chemo work for older breast cancer patients?
- Genetic clues in blood and tumors could personalize breast cancer care
- Can couples coping together ease the burden of advanced cancer?